东方生物
(688298)
| 流通市值：48.93亿 | | | 总市值：48.93亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,430,961,144.02 | 2,500,715,509.52 | 2,604,809,193.17 | 3,081,496,804.8 |
| 交易性金融资产 | 211,686,988.44 | 316,732,715.07 | 328,896,295.38 | 207,578,258.72 |
| 应收票据及应收账款 | 226,662,055.27 | 193,388,585.06 | 192,372,694.5 | 230,166,750.51 |
| 其中：应收票据 | 949,610 | 1,849,025 | 1,276,455 | 2,084,470.32 |
| 应收账款 | 225,712,445.27 | 191,539,560.06 | 191,096,239.5 | 228,082,280.19 |
| 预付款项 | 33,272,652.45 | 36,063,307.39 | 32,136,394.49 | 28,448,863.11 |
| 其他应收款合计 | 10,443,165.29 | 10,855,213.95 | 17,010,163.95 | 19,115,158.73 |
| 存货 | 332,054,222.77 | 313,048,970.1 | 296,948,644.63 | 308,960,712.66 |
| 其他流动资产 | 120,686,454.27 | 116,499,255.51 | 111,736,085.37 | 102,998,159.39 |
| 流动资产合计 | 3,365,766,682.51 | 3,487,303,556.6 | 3,583,909,471.49 | 3,978,764,707.92 |
| 非流动资产: | | | | |
| 长期股权投资 | 18,339,883.43 | 19,144,645.93 | 26,267,094.66 | 20,418,460.71 |
| 其他非流动金融资产 | 30,183,130.55 | 30,122,602.91 | 29,700,752.49 | 29,846,844.66 |
| 固定资产 | 1,677,677,541.83 | 1,512,291,030.11 | 1,526,229,795.9 | 1,541,055,701.04 |
| 在建工程 | 1,112,445,250.68 | 1,242,036,323.01 | 1,228,302,023.42 | 1,134,471,278.02 |
| 使用权资产 | 37,104,514.65 | 40,617,805.32 | 60,390,877.27 | 65,092,573.59 |
| 无形资产 | 930,147,387.62 | 651,719,741.64 | 670,752,732.8 | 690,906,710.19 |
| 长期待摊费用 | 47,881,124.88 | 50,588,936.91 | 54,527,494.18 | 59,710,254.96 |
| 递延所得税资产 | 272,743,992.7 | 268,595,531.72 | 271,730,195.99 | 268,465,824.07 |
| 其他非流动资产 | 15,434,091.52 | 308,200,962.78 | 307,351,513.43 | 305,847,891.38 |
| 非流动资产合计 | 4,141,956,917.86 | 4,123,317,580.33 | 4,175,252,480.14 | 4,115,815,538.62 |
| 资产总计 | 7,507,723,600.37 | 7,610,621,136.93 | 7,759,161,951.63 | 8,094,580,246.54 |
| 流动负债: | | | | |
| 短期借款 | 103,259,685 | 167,962,333.89 | 177,519,344.8 | 116,779,303.25 |
| 应付票据及应付账款 | 479,039,935.78 | 452,982,699 | 480,754,141.22 | 515,489,098.34 |
| 其中：应付票据 | 3,628,182 | - | - | - |
| 应付账款 | 475,411,753.78 | 452,982,699 | 480,754,141.22 | 515,489,098.34 |
| 预收款项 | - | - | 0 | - |
| 合同负债 | 33,251,251.15 | 32,142,326.17 | 35,768,144.35 | 30,987,531.76 |
| 应付职工薪酬 | 41,969,804.99 | 35,913,612.4 | 35,660,662.81 | 61,148,228.76 |
| 应交税费 | 6,200,832.43 | 5,954,684.8 | 9,701,395.04 | 14,895,003.73 |
| 其他应付款合计 | 106,516,944.59 | 114,524,887.06 | 115,334,047.58 | 138,393,080.87 |
| 一年内到期的非流动负债 | 15,110,511.29 | 16,884,465.38 | 30,788,482.47 | 324,816,838.85 |
| 其他流动负债 | 1,226,583.69 | 1,200,613.34 | 1,199,274.34 | 1,292,487.98 |
| 流动负债合计 | 786,575,548.92 | 827,565,622.04 | 886,725,492.61 | 1,203,801,573.54 |
| 非流动负债: | | | | |
| 长期借款 | 159,093,750 | 114,133,950 | 115,133,950 | - |
| 租赁负债 | 28,942,424.39 | 30,179,874.41 | 40,498,031.73 | 47,166,578.69 |
| 长期应付款 | 7,901,664.66 | 7,968,133.12 | 7,678,821.73 | 7,492,019.94 |
| 预计负债 | 6,017,382 | 6,192,900 | 17,622,000 | 17,469,666 |
| 递延收益 | 26,324,176.38 | 26,544,312.6 | 26,771,826.36 | 26,984,585.04 |
| 递延所得税负债 | 54,067.22 | 109,535.33 | 0 | 232,666.69 |
| 非流动负债合计 | 228,333,464.65 | 185,128,705.46 | 207,704,629.82 | 99,345,516.36 |
| 负债合计 | 1,014,909,013.57 | 1,012,694,327.5 | 1,094,430,122.43 | 1,303,147,089.9 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 201,600,000 | 201,600,000 | 201,600,000 | 201,600,000 |
| 资本公积 | 397,885,635.81 | 397,885,635.81 | 397,885,635.81 | 397,885,635.81 |
| 减:库存股 | 326,942,031.65 | 276,947,754.62 | 276,947,754.62 | 276,947,754.62 |
| 其他综合收益 | 33,112,499.33 | 33,076,055.46 | 47,081,400.1 | 54,902,604.6 |
| 盈余公积 | 84,000,000 | 84,000,000 | 84,000,000 | 84,000,000 |
| 未分配利润 | 5,971,018,692.04 | 6,020,553,040.36 | 6,068,198,335.36 | 6,183,650,819.31 |
| 归属于母公司股东权益合计 | 6,360,674,795.53 | 6,460,166,977.01 | 6,521,817,616.65 | 6,645,091,305.1 |
| 少数股东权益 | 132,139,791.27 | 137,759,832.42 | 142,914,212.55 | 146,341,851.54 |
| 股东权益合计 | 6,492,814,586.8 | 6,597,926,809.43 | 6,664,731,829.2 | 6,791,433,156.64 |
| 负债和股东权益合计 | 7,507,723,600.37 | 7,610,621,136.93 | 7,759,161,951.63 | 8,094,580,246.54 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |